Evaluate the Effect of ReSpace™ Hydrogel on Reducing Rectal Radiation Dose in Radiotherapy for Cervical Cancer

Inclusion Criteria: * • Patients with pathologically confirmed cervical cancer who must be scheduled to undergo radical radiotherapy by means of intensity-modulated radiotherapy combined with 3D brachytherapy. * Karnofsky score ≥ 70. * Subjects aged ≥ 18 years and ≤ 75 years. * Subjects must be able to cooperate in completing the entire study. * The subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate MRI. * No contraindications to CT scanning. * Subjects must be able to understand the purpose of the trial, voluntarily participate and sign an informed consent form Exclusion Criteria: * •Subjects who have received prior pelvic radiotherapy. * Subjects whose target tumors have been previously treated (chemotherapy, immunotherapy, surgical treatment, etc.) * Subjects with other primary malignancies * Subjects with contraindications to radiotherapy, as determined by the investigators * Subjects with injection site infections. * Subjects who are allergic to the ingredients of the device. * Subjects whose tumors invade the injection site and affect the injection process and injection safety, as determined by the investigators * Persons with severe mental illness, cognitive impairment and thinking disorders. * Participants in other drug clinical trials or medical device clinical trials 1 month prior to screening * Pregnant or lactating women or those who plan to get pregnant within the last six months * Subjects who cannot be followed up as prescribed by the doctor * Other conditions that, in the judgment of the investigator, make the subject unsuitable for enrollmen